Articles with public access mandates - Humam KadaraLearn more
Not available anywhere: 2
Female gender predicts augmented immune infiltration in lung adenocarcinoma
C Behrens, P Rocha, ER Parra, L Feng, J Rodriguez-Canales, LM Solis, ...
Clinical Lung Cancer 22 (3), e415-e424, 2021
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Integrated Transcriptomic Analysis of Necrosis-related Gene in Diffuse Gliomas
J Wang, J Ma
Journal of Neurological Surgery Part A: Central European Neurosurgery 80 (04 …, 2019
Mandates: National Natural Science Foundation of China
Available somewhere: 90
Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic …
F Skoulidis, LA Byers, L Diao, VA Papadimitrakopoulou, P Tong, J Izzo, ...
Cancer discovery 5 (8), 860-877, 2015
Mandates: US National Institutes of Health, V Foundation, USA
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
T Cascone, WN William Jr, A Weissferdt, CH Leung, HY Lin, A Pataer, ...
Nature medicine 27 (3), 504-514, 2021
Mandates: US National Institutes of Health
The human tumor atlas network: charting tumor transitions across space and time at single-cell resolution
O Rozenblatt-Rosen, A Regev, P Oberdoerffer, T Nawy, A Hupalowska, ...
Cell 181 (2), 236-249, 2020
Mandates: Swiss National Science Foundation, US National Institutes of Health, Howard …
IL6 blockade reprograms the lung tumor microenvironment to limit the development and progression of K-ras–mutant lung cancer
MS Caetano, H Zhang, AM Cumpian, L Gong, N Unver, EJ Ostrin, S Daliri, ...
Cancer research 76 (11), 3189-3199, 2016
Mandates: US National Institutes of Health, LUNGevity Foundation, USA
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up
H Kadara, M Choi, J Zhang, ER Parra, J Rodriguez-Canales, SG Gaffney, ...
Annals of Oncology 28 (1), 75-82, 2017
Mandates: US Department of Defense, US National Institutes of Health
Comprehensive T cell repertoire characterization of non-small cell lung cancer
A Reuben, J Zhang, SH Chiou, RM Gittelman, J Li, WC Lee, J Fujimoto, ...
Nature communications 11 (1), 603, 2020
Mandates: US Department of Defense, US National Institutes of Health, Howard Hughes …
Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinoma
T Cascone, MH Herynk, L Xu, Z Du, H Kadara, MB Nilsson, CJ Oborn, ...
The Journal of clinical investigation 121 (4), 1313-1328, 2011
Mandates: US National Institutes of Health
Ets2 mediated tumor suppressive function and met oncogene inhibition in human non–small cell lung cancer
M Kabbout, MM Garcia, J Fujimoto, DD Liu, D Woods, CW Chow, ...
Clinical cancer research 19 (13), 3383-3395, 2013
Mandates: US National Institutes of Health
EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non–small cell lung carcinoma
C Behrens, LM Solis, H Lin, P Yuan, X Tang, H Kadara, E Riquelme, ...
Clinical cancer research 19 (23), 6556-6565, 2013
Mandates: US National Institutes of Health
High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and mutation
MI Nunez, C Behrens, DM Woods, H Lin, M Suraokar, H Kadara, ...
Journal of thoracic oncology 7 (5), 833-840, 2012
Mandates: US National Institutes of Health
Image analysis–based assessment of PD-L1 and tumor-associated immune cells density supports distinct intratumoral microenvironment groups in non–small cell lung carcinoma patients
ER Parra, C Behrens, J Rodriguez-Canales, H Lin, B Mino, J Blando, ...
Clinical Cancer Research 22 (24), 6278-6289, 2016
Mandates: US National Institutes of Health
Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung
P Yuan, H Kadara, C Behrens, X Tang, D Woods, LM Solis, J Huang, ...
PloS one 5 (2), e9112, 2010
Mandates: US National Institutes of Health
Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome
LM Solis, C Behrens, MG Raso, HY Lin, H Kadara, P Yuan, H Galindo, ...
Cancer 118 (11), 2889-2899, 2012
Mandates: US National Institutes of Health
Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma
X Hu, J Fujimoto, L Ying, J Fukuoka, K Ashizawa, W Sun, A Reuben, ...
Nature communications 10 (1), 2978, 2019
Mandates: US Department of Defense, US National Institutes of Health, Cancer …
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy
G Han, G Yang, D Hao, Y Lu, K Thein, BS Simpson, J Chen, R Sun, ...
Nature communications 12 (1), 5606, 2021
Mandates: US National Institutes of Health, Cancer Research UK, UK Medical Research …
Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer
Y Kudo, C Haymaker, J Zhang, A Reuben, DY Duose, J Fujimoto, ...
Annals of Oncology 30 (9), 1521-1530, 2019
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Pulmonary adenocarcinoma: a renewed entity in 2011
H Kadara, M Kabbout, II Wistuba
Respirology 17 (1), 50-65, 2012
Mandates: US National Institutes of Health
Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function
M Choi, H Kadara, J Zhang, ER Parra, J Rodriguez-Canales, SG Gaffney, ...
Annals of Oncology 28 (1), 83-89, 2017
Mandates: US Department of Defense, US National Institutes of Health
Publication and funding information is determined automatically by a computer program